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Abstract
Introduction: Metastatic tumors to the spleen are rare but are usually found in conjunction with metastasis to
other organs. The most common sources of splenic metastasis are breast, lung and colorectal cancers as well as
melanoma and ovarian carcinoma. A solitary carcinosarcoma metastasis to the spleen of any origin is very rare. To
the best of our knowledge, there are fewer than 30 reported cases of ovarian primary tumors with solitary
metastasis to the spleen, and only three solitary primary carcinosarcomas to the spleen have been reported, of
which one is female. We present what is, to the best of our knowledge, the first case of a solitary metastatic
carcinosarcoma to the spleen arising from a primary ovarian carcinsarcoma.
Case presentation: A 72-year-old Hispanic woman status post-total abdominal hysterectomy for ovarian
carcinosarcoma presented with complaints of early satiety and abdominal pain for the past two months with a
30-lb unintentional weight loss. An initial computed tomographic scan of her abdomen and pelvis revealed a
30 cm × 27 cm splenic mass with displacement of the left kidney, stomach and liver. The patient was found to
have a solitary metastatic carcinosarcoma of the spleen with biphasic epithelial (carcinomatous) and mesenchymal
(sarcomatous) elements consistent with carcinosarcoma.
Conclusion: Carcinosarcoma of the spleen is a rare tumor. Carcinosarcomas are a biphasic neoplasm comprising
malignant epithelial and mesenchymal components arising from a stem cell capable of differentiation. They can
arise anywhere in the female genital tract, most commonly from the endometrium. Even though it is rare,
carcinosarcomas can metastasize to the spleen. This unique case of a solitary splenic metastasis from ovarian
carcinosarcoma has particular interest in medicine, especially for the specialties of surgical oncology, pathology and
hematology/oncology.
Introduction
The most common malignancy arising from the spleen is
lymphoreticular. Malignant nonlymphoreticular neo-
plasms involving the spleen are rare. Splenic metastases
from solid tumors occur in late stages of a disease process,
are due to hematogenous dissemination confined to the
splenic parenchyma and are usually found in conjunction
with metastases to other organs [1]. The most common
primary sources include breast, lung, stomach, colorectal
and ovarian cancers and melanoma [1,2]. Solitary splenic
metastases have been documented in 93 patients. In
regard to ovarian tumors, there are fewer than 30 cases of
solitary parenchymal metastases reported in the literature.
The most common histologic type seen in these patients is
serous cystadenocarcinoma [3]. Carcinosarcoma is typi-
cally an extremely aggressive neoplasm histologically com-
prising epithelial (carcinomatous) and mesenchymal
(sarcomatous) elements. Westra et al. [4] were the first to
report a solitary primary carcinosarcoma to the spleen in a
woman. The other two cases of primary carcinosarcomas
of the spleen were reported in men [5,6]. We present a
case of a metachronous solitary splenic metastasis from
ovarian carcinosarcoma.
Case presentation
A 72-year-old Hispanic woman presented with com-
plaints of early satiety and abdominal pain for the past
two months with a 30-lb unintentional weight loss. Her
medical history included a total abdominal hysterectomy
with bilateral salpingo-oophorectomy performed in
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pathology report described an ovarian carcinosarcoma.
Her physical examination revealed a large left upper
quadrant mass which was tender to palpation. An initial
computed tomographic scan of her abdomen and pelvis
revealed a 30 cm × 27 cm splenic mass in coronal view
with displacement of the left kidney, stomach and liver
(see attached arrow in Figure 1). No other masses con-
cerning metastasis were noted.
Prior to her splenectomy and after appropriate vacci-
nation (Menomune
® {A/C/Y/W-135, Meningococcal
Polysaccharide Vaccine, Groups A, C, Y and W-135
Combine, Manufacturer Sanofi Pasteur located in Swift-
water, Pennsylvania, United States of America}, ActHIB
®
{ Haemophilus b Conjugate Vaccine Manufacturer
located Sanofi Pasteur located in Swiftwater, Pennsylva-
nia, United States of America} and Pneumovax 23
®
{pneumococcal vaccine polyvalent, Manufacturer
MERCK located in Whitehouse Station, New Jersey,
United States of America}), the patient underwent
embolization of her splenic artery as a cautious
approach to prevent hemorrhage.
In addition to the planned splenectomy, a partial gas-
trectomy was performed because the splenic tumor
directly invaded the proximal stomach. The splenic
mass was delivered en bloc and without evidence of rup-
ture. The specimen weighed 4.2 kg and had a grossly
intact capsule beside the region in which it had invaded
the stomach (Figure 2). The gross specimen measured
30 cm × 27 cm × 20 cm. Estimated blood loss was
2200 mL secondary to bleeding. A total of eight units of
packed red blood cells, four units of fresh frozen plasma
and two units of platelets were administered during the
procedure. Post-operatively, the patient did well. She
was extubated on post-operative day four. An upper gas-
trointestinal gastrograffin study showed no overt extra-
luminal contrast. The patient’s symptoms of early satiety
were relieved and her diet was advanced slowly. Her
pathology demonstrated a carcinosarcoma with malig-
nant stromal and epithelial components consistent with
ovarian origin heterologous cartilage (original magnifica-
tion, × 20; hematoxylin and eosin stain) (Figure 3).
Figure 1 A computed tomographic scan of a large splenic
mass (coronal view). See attached arrow.
Figure 2 Gross specimen measuring 30 cm × 27 cm × 20 cm
(4.2 kg).
Figure 3 Biphasic tumor with malignant stromal and malignant
epithelial component, heterologous (original magnification, ×
20; hematoxylin and eosin stain).
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The incidence of splenic metastases is between 2.3% and
7.1% [1]. Solitary metastasis to the spleen is secondary
to hematogenous dissemination and is confined to the
splenic parenchyma. The most common primary sources
include breast, lung, stomach, ovarian and colorectal
cancers and melanoma [1,2]. Skin melanoma has the
highest rate of splenic metastases per primary tumor.
More than 30% of patients with skin melanoma have
splenic metastasis at autopsy [3]. Solitary splenic metas-
tases have been reported in 93 cases. The time from the
diagnosis of primary tumor to the discovery of solitary
splenic metastasis ranges from zero to 264 months with
a median of 28 months [7]. Colorectal and ovarian car-
cinomas are the most common sources of splenic
metastases other than melanoma. In regard to ovarian
carcinoma, the most prevalent type is serous cystadeno-
carcinoma, which has been reported in 17 cases [7].
Carcinosarcomas are tumors composed of both malig-
nant epithelial and mesenchymal elements, and they
arise primarily from the female reproductive tract. Car-
cinosarcomas with or without heterologous components
typically have poorly differentiated endometrioid or ser-
ous histology and are often associated with p53 gene
mutations [8]. Our patient’s spleen showed a biphasic
tumor composed of epithelial (carcinomatous) and
mesenchymal (sarcomatous) elements consistent with
carcinosarcoma. It is believed that the mesenchymal
component differentiates from the epithelial component
via a metaplastic process. The tumor did contain hetero-
logous elements (that is, cartilage) in our case. Micro-
scopic examination showed large strands and cords of
anaplastic cells with pleomorphic nuclei. There was no
involvement of the splenic capsule; however, the tumor
was found to invade the serosa of the stomach with
extension into the muscular propia with portions also
involving the mucosa.
The pathogenesis of carcinosarcoma is poorly under-
stood. Only two opposing theories have received strong
support to explain the histological features found in this
type of tumor. The monoclonal theory stipulates that
these tumors are undifferentiated and have the capabil-
ity to develop mesenchymal and epithelial components.
On the other hand, the multiclonal theory supports the
hypothesis that two separate cell lines fuse and differ-
entiate into a single tumor [2,9]. It is important to dis-
tinguish a true carcinosarcoma from a collision tumor,
in which a carcinoma and sarcoma arise in close proxi-
mity to one another. These tumors arise from different
sources, forming a tumor border and never truly com-
mingling [2,10]. Synchronous sarcoma and carcinoma
arise from separate stem cells and merge in a biclonal
process [9]. In our case, there was a single mass with
mixed epithelial and mesenchymal components resem-
bling a malignant Müllerian tumor, thus ruling out a
collision tumor.
The pathogenesis of solitary splenic metastasis is
unknown. The rarity of solitary splenic metastasis might
be explained by (1) mechanical factors impeding hema-
togenous implantation of neoplastic cells because of the
flow and course of blood through the splenic vascula-
ture and (2) an inhibitory effect of the splenic microen-
vironment on neoplastic cells [1,7]. Other hypotheses
that can explain the scarcity of splenic metastasis
include the acute angle of the origin and tortuosity of
the splenic artery, the role of the splenic capsule as a
physical barrier, the lack of afferent lymphatics to the
splenic metastasis and its rhythmic contractile properties
[11].
Splenic metastases may occur by direct extension,
transperitoneal spread, hematogenous route or lympha-
togenous route or by a combination of these phenom-
ena. The main metastatic pathway to the spleen is
hematogenous, and it is generally accepted that by the
time a metastatic tumor is found in the spleen, multiple
secondary tumors can be found in other organs. Splenic
metastasis is often associated with terminal cancer, and
isolated splenic metastasis is rare [12]. Implantation of
cancer cells in the splenic parenchyma may occur at the
time of primary diagnosis but is clinically undetectable
because the splenic microenvironment may not facilitate
the growth of micrometastatic foci [3].
On the basis of gross and microscopic descriptions,
splenic metastases can be categorized according by the
type of splenic invasion: parenchymal-only, capsular or
capsular with parenchymal invasion [11]. Ovarian cancer
generally metastasizes via the lymphatic system or by
peritoneal dissemination. As far as splenic metastasis of
this malignancy is concerned, while disseminated lesions
can sometimes be seen on the surface of the spleen, par-
enchymal splenic metastasis of ovarian cancer is rela-
tively rare, and solitary metastasis is even rarer [13].
They can present as a solitary splenic mass synchronous
or metachronous to the primary tumor. Our case is an
example of a metachronous solitary splenic metastasis.
Splenic metastases are most often incidentally detected
by ultrasonography or computed tomography in follow-
up of cancer patients or in the work-up performed of
any event related to cancer. Splenic metastases are a
part of multi-visceral metastatic disease. Metastatic
tumor of the spleen diagnosed in patients with wide-
spread visceral dissemination of primary tumor has no
clinical importance, because the overall prognosis is very
poor. However, splenectomy can be performed as a pal-
liative treatment option in those patients with sympto-
matic splenomegaly [7].
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apy is debatable. Because of the rarity of this condition,
no randomized trials have been conducted to determine
the best therapy. The median overall survival in ovarian
carcinosarcoma appears to be extended with the use of
platinum-based therapies [14]. The recently published
phase II Gynecologic Oncology Group (GOG) study
[15] of single-agent cisplatin as initial chemotherapy in
ovarian carcinosarcoma had 136 eligible patients
enrolled between 1977 and 1996, underscoring the rarity
o ft h e s et u m o r sa n dt h ed i f f i c u l t yo fe n r o l l m e n to f
patients into prospective clinical trials. The GOG study
showed an overall response rate of 20% with single-
agent cisplatin, providing the first prospective evidence
that platinum is active as an initial therapy for patients
with carcinosarcoma of the ovary [15].
Duska et al. [16] reported on 28 patients (including
two patients with recurrent disease) treated with plati-
num and taxane who had a total response rate of 72%.
The overall median survival for the 28 patients was 27.1
months. Rutledge et al. [14] reported on 29 patients
receiving adjuvant chemotherapy, with 11 patients
receiving platinum and ifosfamide and 16 patients
receiving platinum and a taxane. The overall survival
w a s2 1m o n t h sf o rt h ee n t i r eg r o u p ,a n dt h er e s p o n s e
rate was not detailed in the report. Though overall sur-
vival was improved with the use of ifosfamide and cis-
platin for the entire cohort, there was no significant
advantage for the advanced stage group, and multivari-
ate analysis did not identify any statistically significant
predictor of outcome [14].
Conclusions
C a r c i n o s a r c o m a sa r eab i p h a s i cn e o p l a s mc o m p r i s i n g
malignant epithelial and mesenchymal components aris-
ing from a stem cell capable of differentiation. The most
common sources of splenic metastasis are breast, lung,
colorectal and ovarian carcinomas as well as melanoma.
They can arise anywhere in the female genital tract,
most commonly from the endometrium. It must be
noted again that because of the rarity of this condition,
there is no consensus on the appropriate chemotherapy
regimen. Complete surgical resection appears to offer
the best chance of long-term survival. Carcinosarcoma
o ft h es p l e e ni sar a r et u m o r .O n l yt h r e ec a s e so fs o l i -
tary primary carcinosarcomas of the spleen have been
reported. To the best of our knowledge, this is the first
reported case of a metachronous solitary splenic metas-
tasis from ovarian carcinosarcoma.
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